The results vaulted Nektar’s market value to over $1 billion amid expectations the drug might prove a challenger to widely ...

Nektar Therapeutics today announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of rezpegaldesleukin, a novel regulatory T-cell (Treg) biologic, in ...

The newly public Evommune shared data showing that EVO301, an IL-18 targeting protein, cleared symptoms comparably to Regeneron and Sanofi’s mega-blockbuster in a mid-stage atopic dermatitis clinical ...

IPO stock Evommune roughly doubled Tuesday on positive results for its intravenously infused eczema treatment.

Evommune (EVMN) stock surges as the company posts a mid-stage trial win for its experimental drug targeting atopic dermatitis ...

High-frequency wands use low-level electrical currents to kill acne-causing bacteria and reduce inflammation. At-home devices offer more convenience but less dramatic results than in-office ...

Investing.com -- Evommune Inc. (NYSE:EVMN) stock soared 64% after the clinical-stage biotechnology company announced positive top-line results from its Phase 2a trial evaluating EVO301 in patients ...

An eczema drug from Nektar Therapeutics maintained skin responses in a one-year study, meeting and in some cases exceeding ...

Jutta Leerdam wins Olympic speedskating gold as fiance Jake Paul sobs Comedian Bill Maher regrets rift with Jimmy Kimmel, worries they may never speak again Georgia judge issues emergency warning tied ...

Eng managed to isolate the molecule responsible, a protein called exendin-4 bearing a remarkable resemblance to human glucagon-like-protein-1 (GLP-1), which stimulates insulin production. When ...

Ependymomas are tumors that grow in the brain or spinal cord and are the third-most common type of brain tumor in children. This type of cancer affects about 250 children in the United States each ...

An experimental combo drug from Novo Nordisk leads to more weight loss than semaglutide alone, according to late-stage trial data.